Back
Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome.
Journal article

Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome.

  • Corti D Humabs BioMed SA, 6500 Bellinzona, Switzerland. Electronic address: davide.corti@humabs.ch.
  • Passini N Humabs BioMed SA, 6500 Bellinzona, Switzerland.
  • Lanzavecchia A Immune Regulation Unit, Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland; Institute of Microbiology, Eidgenössische Technische Hochschule Zurich, 8093 Zurich, Switzerland.
  • Zambon M Microbiology Services Colindale, Public Health England, London NW9 5HT, United Kingdom.
  • 2016-04-23
Published in:
  • Journal of infection and public health. - 2016
Animals
Antibodies, Monoclonal
Antibodies, Viral
Biotechnology
CHO Cells
Coronavirus Infections
Cricetulus
Humans
Immunologic Factors
Immunotherapy
Technology, Pharmaceutical
Time Factors
English The last century has witnessed the emergence of several previously unknown viruses as life-threatening human pathogens. Several examples include HIV, Ebola, Lujo, and, most recently, the Middle East respiratory syndrome (MERS) and Ebola. In this study, we describe a method for the swift generation of a human-derived monoclonal antibody, known as LCA60, as a treatment for MERS infections. LCA60 antibody was generated using the Cellclone Technology from the immortalized B cells of a human donor recovering from MERS. Only four months were required from the initial screening of B cells to the development of a stable CHO cell line suitable for the production of clinical grade antibody, thereby delineating a rapid pathway for the development of antiviral therapies against emerging viruses. Currently, the LCA60 antibody is being considered for clinical development, which includes prophylaxis in individuals at risk and a treatment for severe MERS-CoV infections.
Language
  • English
Open access status
gold
Identifiers
Persistent URL
https://sonar.ch/global/documents/185295
Statistics
Document views: 12 File downloads: